The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many ...

In its latest earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its ...

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines ...

Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office ...